Xencor
Xencor Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, utilizing its proprietary XmAb technology platform to improve antibody therapeutic properties. The company designs novel protein therapeutics designed to enhance immune system response against tumors and extend half-life in circulation. Its core business operations encompass biopharmaceutical protein engineering, clinical trial execution, drug formulation development, and licensing partnerships with major pharmaceutical enterprises. As a clinical-stage biotechnology enterprise, the company generates revenue through technology licensing fees, milestone payments, and collaborative research agreements. XmAb technology is incorporated in several approved commercial drugs worldwide. Xencor holds a pioneering market position in protein engineering and antibody therapeutics. The company is headquartered in Monrovia, California, United States, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Xencor.
- Legal name
- XENCOR
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Xencor
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.17 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)